Latest Hotspot

Eirion Therapeutics Begins First Human Trials for Topical ET-02 in Androgenic Alopecia Treatment

9 July 2024
3 min read

Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia. This placebo-controlled, double-blind trial seeks to evaluate the safety profile of ET-02 when applied once daily over a 28-day period. The trial plans to enlist around 24 participants across three research sites within the United States.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

ET-02 operates with a unique mechanism of action aimed at reactivating hair follicle stem cells that have become defective or inactive in men experiencing age-related hair loss, restoring them to their normal function. These hair follicle stem cells are crucial as they act as “master control switches” for hair growth. By reactivating these stem cells, it is anticipated that normal hair growth can be resumed. ET-02 addresses what the Company identifies as the root cause of androgenic alopecia, with expectations that this treatment could be notably more effective than current treatments that do not directly impact hair follicle stem cells.

"Considering its hypothesized mechanism, ET-02 could represent a significant advancement over existing pharmaceutical options for treating androgenic alopecia," stated Jerry Shapiro, MD, a renowned expert in hair loss treatment and Professor of Dermatology at New York University Grossman School of Medicine.

Jon Edelson, MD, CEO and President of Eirion, remarked, "A controlled pre-clinical study of ET-02 on 90 human scalp tissue grafts from men with intermediate-stage androgenic alopecia exhibits this pharmaceutical’s potential in restoring hair growth and normalizing hair follicle structure and function. Due to its distinct mechanism, we believe ET-02 not only has the potential to treat but also to prevent androgenic alopecia."

In contrast to some other market-available treatments, ET-02 does not target hormonal pathways and is not expected to cause the side effects commonly associated with those treatments, such as sexual dysfunction.

"ET-02 complements our other two aesthetic bio-pharmaceutical products under development, both of which are potential treatments for facial wrinkles. Together, these three product candidates establish a strong and promising pipeline for innovation in aesthetic medicine," added Dr. Edelson. 

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of July 8, 2024, there are 752 investigational drugs for the CD19 target, including 229 indications, 486 R&D institutions involved, with related clinical trials reaching 1177, and as many as 42074 patents.

ET-02 targets of CD19 for the treatment of neoplasms, immune system diseases, and hemic and lymphatic diseases. However, the development of the drug has been discontinued in both the global and Chinese markets. 

图形用户界面, 文本, 应用程序

描述已自动生成

Is Inmazeb approved by the FDA?
Drug Insights
2 min read
Is Inmazeb approved by the FDA?
9 July 2024
Approved on October 14, 2020, it provides a crucial option for managing and treating Ebola virus disease.
Read →
Global New Drug Research and Development Progress Weekly Report(7.1-7.7)
Drug Highlight
10 min read
Global New Drug Research and Development Progress Weekly Report(7.1-7.7)
8 July 2024
7.1-7.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
Is Pralsetinib approved by the FDA?
Drug Insights
3 min read
Is Pralsetinib approved by the FDA?
5 July 2024
Approved on September 4, 2020, pralsetinib (Gavreto) represents a significant advancement in targeted cancer therapy.
Read →
What are the prospects for the AOC therapy that boosted Avidity by 33%?
Hot Spotlight
10 min read
What are the prospects for the AOC therapy that boosted Avidity by 33%?
5 July 2024
Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.